This together with the AVATAR readout may get us there even before the EXCELLENCE readout, although I suspect a package deal with the FDA/TGA/EMA using data from all 3 trials.
Oh and I need to update the definition of mid-year.
Will be very interesting to see how the score is in the AVATAR high-dose trial.
a tremendous NR this a.m. with vast implications for not only RETT but a full spectrum of rare diseases, [some of which are (will be) billion dollar money makers.] There are approximately 200 so called rare CNS diseases. How many can this platform drug (?) impact?
Let alone Parkinson's and Alzheimers.
A new frontier in science being discovered and established with massive CNS patient changes. Going, as Kirk said, where no man has gone before................."to seek out new life."
The quality of our invention is real. BIIB gonna get a whoopin.
from the NR: Despite the challenges of the older age of the cohort (patients were on average 24 years of age) and the relatively low dose (5 mg daily), ANAVEX®2-73 demonstrated clinically meaningful improvements in outcome measures evaluating multiple impairments, which are supported by correlations with objective biomarkers.”
(The results described below should dramatically increase the success rate of the upcoming AD & PDD trials)
“The biomarker-driven clinical evidence is very exciting and opens the possibility of successful treatment for both adults and children with Rett syndrome and early interventions for modifying the course of the disease,” commented Walter E. Kaufmann, MD, Principal Investigator and Chief Medical Officer of Anavex. “The outcome of this trial is very promising in terms of both safety and clinical improvement. Despite the challenges of the older age of the cohort (patients were on average 24 years of age) and the relatively low dose (5 mg daily), ANAVEX®2-73 demonstrated clinically meaningful improvements in outcome measures evaluating multiple impairments, which are supported by correlations with objective biomarkers.”
With this convincing biomarker correlating efficacy dataof U.S. Phase 2 (ANAVEX®2-73-RS-001)7 study in adult patients with Rett syndrome, Anavex is planning to meet with the FDA to discuss the approval pathway. There are no FDA-approved drugs for Rett syndrome. ANAVEX®2-73 has Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome and may be considered for accelerated approval. The study was supported by the Rettsyndrome.org Foundation.
ANAVEX®2-73 is currently being evaluated for Rett syndrome in two other ongoing late-stage placebo-controlled clinical studies: The AVATAR trial in adult Rett syndrome (ANAVEX®2-73-RS-002)8 and the EXCELLENCE pediatric Rett syndrome trial (ANAVEX®2-73-RS-003)9.
“These are strong and consistent data demonstrating biomarker-correlated rapid and clinically meaningful improvements in key measures of Rett syndrome symptoms in the ANAVEX®2-73 treatment group compared to placebo,” said Christopher U. Missling, PhD, President & Chief Executive Officer of Anavex. “Our team is dedicated to provide for this urgent unmet need of patients with Rett syndrome, and we believe our ANAVEX®2-73 Rett syndrome program sets us on a course to potentially offer a new, unique and mechanistically differentiated treatment option also for other diseases associated with autism spectrum disorder.”
Anavex Life Sciences’ product portfolio platform includes small molecule drug lead candidate ANAVEX®2-73 for the treatment of Alzheimer’s disease, Parkinson’s disease and Rett syndrome and ANAVEX®3-71 for frontotemporal dementia.